Alyssa Reddy

MD

Pediatric neurologist
Pediatric neuro-oncologist
Director, UCSF Neurofibromatosis Program
Passionate about curing brain cancer and all things outdoors

Dr. Alyssa Reddy is a pediatric neurologist with expertise in treating children who have tumors of the central nervous system. She has more than 20 years of experience in diagnosing and managing brain tumors and other neurologic disorders. She cares for children and young adults in both the clinic and the hospital.

Reddy directs UCSF's program in neurofibromatosis, a genetic disorder in which tumors form on nerves and can affect many elements of the body, including skin, bones and senses such as hearing. She aims to provide patients with compassionate care as well as access to cutting-edge treatment.

Reddy's research has focused mainly on improving long-term survival and quality of life for children with brain tumors. She believes these goals are best accomplished through a collaborative approach from a diverse team of scientists and health care providers with the ability to offer new therapies through clinical trials.

After earning her medical degree from the University of Alabama at Birmingham School of Medicine, Reddy completed a residency in pediatrics at the Children's of Alabama. She completed fellowships in child neurology at Children's of Alabama and in neuro-oncology at the Children's National Medical Center. She is a member of the Children's Oncology Group, Society for Neuro-Oncology and Child Neurology Society.

In college, Reddy participated in track and cross-country, where she met her husband, Michael. They have three children, Alex, Rachael and Brooks, who each live in a different state. Reddy enjoys spending time with family, traveling and being outdoors.

  • Education

    University of Alabama at Birmingham School of Medicine, 1993

  • Residencies

    Children's of Alabama, Pediatrics, 1995

  • Fellowships

    Children's of Alabama, Child Neurology, 1998

    Children's National Medical Center, Neuro-Oncology, 1998

  • Board Certifications

    Child Neurology, American Board of Psychiatry and Neurology.

  • Academic Title

    Professor

Where I see patients (1)

    Selected research

    See all research
    Decorative Caduceus

    A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

    Will be measured by the number of progressions or deaths within 2 years of enrollment for the cohort treated with whole ventricular + spinal canal irradiation (WVSCI). The final analysis will include an exact binomial confidence i...

    Recruiting

    Decorative Caduceus

    A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for Primary C...

    We will estimate the difference in mean Cogstate composite Z score slopes (reflecting change in Cogstate composite Z scores from baseline to 12 months post baseline taking into account measurements at those time points as well as ...

    Recruiting

    Decorative Caduceus

    A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse I...

    Defined as the highest dose of selinexor in combination with standard of care radiation therapy (RT) that does not cause unacceptable side effects.

    Recruiting

    Decorative Caduceus

    A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromato...

    EFS is defined as time from randomization to the first occurrence of any of the following events: clinical or radiographic disease progression, disease recurrence, second malignant neoplasm, or death from any cause. Patients who a...

    Recruiting

    Decorative Caduceus

    A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Gli...

    The Kaplan-Meier method will be used to estimate EFS which is defined as the interval from randomization to first occurrence of clinical or radiographic disease progression, disease recurrence, second malignant neoplasm, or death ...

    Recruiting

    Decorative Caduceus

    Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

    Based on Response Evaluation in Solid Tumors (RECIST) version 1.1

    Recruiting

    Contact me

    Share